Work

Paradoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistance

Year: 2016

Type: article

Abstract: Lung cancer is the leading cause of cancer-related death in the United States and worldwide. While the 5-year survival for lung cancer is a dismal 15%, there have been significant advances in treating patients with non-small cell lung cancer (NSCLC) in the past decade. These recent advances stem from the shift to classifying patients with NSCLC into distinct subtypes based upon the molecular driver, which include KRAS mutations (~25%), EGFR mutations (~15%), ALK translocations (~8%), and MET amplification/mutations (~6-7%) (1,2).

Source: Journal of Thoracic Disease

DOI: 10.21037/jtd.2016.11.59

Authors: Zachary A. Yochum, Mark A. Socinski, Timothy F. Burns

Institutions: University of Pittsburgh, Florida Hospital Cancer Institute, UPMC Hillman Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: Doris Duke Charitable Foundation, Zhejiang University, National Institute of General Medical Sciences